How Direct-To-Patient Models Can Provide Clinical Supply Chains With An End-To-End Solution

Analyzing the benefits and challenges of implementing direct-to-patient services in the clinical supply chain to help meet patient requirements, improve supply chain efficiency and accelerate speed to market

The importance of direct-to-patient services in modern clinical trial delivery

If a “rare” disease affects approximately 10 percent of the global population, or approximately 475 million people, just five percent of those affected will have access to treatment, according to the World Economic Forum. The uncertainty raised by the coronavirus pandemic has forced the pharma industry to turn its resources toward strengthening its clinical trial supply chains and improving patient access to care. In doing so, the industry has deepened its focus on patient-centricity and has expanded treatment options available for unknown diseases.

The traditional clinical trial model can pose a number of challenges that hinder the development of a clinical trial process in the modern world. For example, patients may find it difficult to book adequate time off to participate and recover from the trial, while ensuring all travel costs are covered and arrangements to travel to the clinical site can pose additional challenges.